Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1823802,
author = {Matkulčík, Peter and Uher, Michal and Rohan, Tomáš and Straka, Matej and Andrašina, Tomáš},
booktitle = {CIRSE 2021},
keywords = {biliary tract; metal stent; malignancy; survival analysis; cholangiocarcinoma},
language = {eng},
title = {Biliary metal stent patency rate: long term national analysis},
url = {https://link.springer.com/content/pdf/10.1007/s00270-021-02939-6.pdf},
year = {2021}
}
TY - CONF
ID - 1823802
AU - Matkulčík, Peter - Uher, Michal - Rohan, Tomáš - Straka, Matej - Andrašina, Tomáš
PY - 2021
TI - Biliary metal stent patency rate: long term national analysis
KW - biliary tract
KW - metal stent
KW - malignancy
KW - survival analysis
KW - cholangiocarcinoma
UR - https://link.springer.com/content/pdf/10.1007/s00270-021-02939-6.pdf
N2 - urpose: To evaluate biliary metal stent patency rate in biliary malignancies related to the frequency of biliary metal stent insertion in the hospital. Materials and Methods: All reported patients with biliary tract malignancy treated with metal stent insertion in Czechia in 2010-2018 were enrolled in this retrospective analysis. According to frequency of metal stent insertion hospitals in Czechia were divided into 3 groups (over 54; 20-54; less than 20 metal stent implantations). Except metal stent patency rate (log rank test), possible risk factors like age, gender, anatomical location of biliary cancer and its stage were analyzed (uni and multivariate analysis, Cox-regression). Results: 562 patients with median biliary metal stent patency rate of 4.2 months (95%CI 3.5-4.9) while 106 patients underwent metal stent recanalization and 456 patients died without recanalization. Metal stent patency rate was signifcantly better in hospitals with 55 and more implanted stents compared to hospitals with 20-54 and less than 20 implanted stents during the study period (median patency 5.8 vs 3.2 vs 3.7 months, p=0.004 and p=0.012). Worse patency rate was further observed in gall bladder cancer (HR 1.431(95%CI 1.152-1.778), p=0.001) and advanced stages of biliary malignancy (HR in TNM stage 2,3 and 4 were 1.447(95%CI 1.044-2.005), 1.257(95%CI 0.885-1.784), and 1.914(95%CI 1.410-2.598)). Conclusion: Reported biliary metal stent patency rate in biliary cancer was signifcantly better in hospitals with higher frequency of metal stent implantations.
ER -
MATKULČÍK, Peter, Michal UHER, Tomáš ROHAN, Matej STRAKA a Tomáš ANDRAŠINA. Biliary metal stent patency rate: long term national analysis. In \textit{CIRSE 2021}. 2021.
|
